The estimated Net Worth of Noah G.Newtyn Management, L... is at least $16.9 Milione dollars as of 12 January 2023. Mr. L owns over 100,000 units of Merrimack Pharmaceuticals Inc stock worth over $16,939,336 and over the last 5 years he sold MACK stock worth over $0. In addition, he makes $0 as Independent Director at Merrimack Pharmaceuticals Inc.
Noah has made over 23 trades of the Merrimack Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of MACK stock worth $1,190,000 on 12 January 2023.
The largest trade he's ever made was buying 177,274 units of Merrimack Pharmaceuticals Inc stock on 22 July 2020 worth over $551,322. On average, Noah trades about 30,458 units every 44 days since 2020. As of 12 January 2023 he still owns at least 1,119,586 units of Merrimack Pharmaceuticals Inc stock.
You can see the complete history of Mr. L stock trades at the bottom of the page.
Noah G. Levy serves as Independent Director of the Company. He has served as a member of our board of directors since September 2019. Mr. Levy has been a managing member and portfolio manager at Newtyn Management, LLC, an investment firm, since June 2011. Prior to that, Mr. Levy served as a senior member at Tyndall Management, an investment firm, from 2002 to 2011, and as an analyst at Goldman Sachs, an investment bank and financial services company, from 2000 to 2002. Mr. Levy holds a B.A. from Dartmouth College.
Noah Levy is 42, he's been the Independent Director of Merrimack Pharmaceuticals Inc since 2019. There are 10 older and no younger executives at Merrimack Pharmaceuticals Inc. The oldest executive at Merrimack Pharmaceuticals Inc is Dr. Anthony J. Sinskey Ph.D., Sc.D., 81, who is the Co-Founder and Scientific Advisor.
Over the last 13 years, insiders at Merrimack Pharmaceuticals Inc have traded over $1,152,598 worth of Merrimack Pharmaceuticals Inc stock and bought 3,978,994 units worth $28,464,218 . The most active insiders traders include Eric Western Standard Llcwe..., Robert J. Mulroy e Gary L Crocker. On average, Merrimack Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $459,997. The most recent stock trade was executed by Eric Western Standard Llcwe... on 26 December 2023, trading 49,550 units of MACK stock currently worth $651,583.
merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.
Merrimack Pharmaceuticals Inc executives and other stock owners filed with the SEC include: